|本期目录/Table of Contents|

[1]谭 丹,曾小琴,徐 伟,等.姜黄素对肺癌A549细胞迁移和侵袭的影响[J].中华肺部疾病杂志,2020,(03):314-318.[doi:10.3877/cma.j.issn.1674-6902.2020.03.005]
　Lu Xiaoqian,Meng Fanyang,Dou Le,et al.Correlation study on multi-slice spiral computed tomography findings and epidermal growth factor receptor mutations in patients with lung adenocarcinoma[J].,2020,(03):314-318.[doi:10.3877/cma.j.issn.1674-6902.2020.03.005]
点击复制

姜黄素对肺癌A549细胞迁移和侵袭的影响(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2020年03期
页码:
314-318
栏目:
论著
出版日期:
2020-06-20

文章信息/Info

Title:
Correlation study on multi-slice spiral computed tomography findings and epidermal growth factor receptor mutations in patients with lung adenocarcinoma
作者:
谭 丹1; 曾小琴2; 徐 伟1; 陈 戬3; 周人杰1
400037 重庆,陆军(第三)军医大学第二附属医院急诊与全科医学中心1 呼吸与危重症医学科2、全军免疫学研究所3
Author(s):
Lu Xiaoqian;  Meng Fanyang;  Dou Le;  Cao Dianbo.
Radiology Department, First Affiliated Hospital, Jilin University, Changchun 130021, China
关键词:
姜黄素;  支气管肺癌;  A549细胞;  迁移;  侵袭;  EMT
Keywords:
Epidermal growth factor receptor;  Lung tumor;  Multi-slice spiral computed tomography
分类号:
R285.5
DOI:
10.3877/cma.j.issn.1674-6902.2020.03.005
摘要:
目的 探讨周围型肺腺癌患者CT影像及临床病理特征与表皮生长因子受体(EGFR)突变的相关性。方法 分析2017年9月至2018年4月于我院胸外科行手术治疗、术后病理确诊为周围型肺腺癌,并对术后大体病理标本进行EGFR基因检测的157例患者。由两名高年资影像科医生分别独立对术前一个月内胸部CT阅片分析,评估其影像特征,并结合临床、病理特征探讨EGFR突变的相关因素,利用Fisher精确检验、χ2检验、t检验、绘制ROC曲线进行分析,P<0.05为差异有统计学意义。结果 EGFR突变在MSCT影像表现中,有毛刺组突变率为65.1%(P=0.012),有胸膜凹陷组为64.6%(P=0.044),有磨玻璃影组为70.3%(P=0.013),具有统计学差异。女性患者中EGFR突变占68.0%(P=0.002),不吸烟患者中占69.2%(P=0.000),腺泡型、贴壁型、微乳头型、乳头型、实性型、浸润性粘液型,EGFR突变率分别为:68.5%、60.9%、50.0%、43.8%、22.2%、0.0%(P=0.003),差异有统计学意义。多变量回归分析显示:将所有显著特征统一预测EGFR突变时,ROC曲线的AUC为0.718。结论 原发性肺腺癌患者,EGFR突变易发生于女性不吸烟患者中,在腺泡型、贴壁型病理亚型易发生。影像学上伴有磨玻璃影,病灶边缘有毛刺、胸膜凹陷征的肿瘤易发生EGFR突变。
Abstract:
Objective To investigate the correlation of clinical, pathological and multi-slice spiral computed tomography(MSCT)findings and epidermal growth factor receptor(EGFR)mutations in the patients with lung adenocarcinoma. Methods A total of 157 patients with lung adenocarcinoma who underwent surgery and were confirmed to suffer from peripheral lung adenocarcinoma pathologically after operation in the Department of Chest Surgery in our hospital from September 2017 to April 2018 were collected for this study. The EGFR status was respectively tested for the postoperative specimens. Two senior radiologists independently analyzed the chest preoperative MSCT within one month and evaluated the relevant factors of EGFR mutations through analyzing the clinical information and the pathological features. All the data were analyzed with Chi-squared test, Fisher's exact test, and Student's t test. The ROC curves were statistically analyzed. And P<0.05 was considered statistically significant. Results On the CT images, the mutation rates of EGFR in the tumors with spiculation, pleural indentation and ground-glass opacity(GGO)were 65.1%(P=0.012), 64.6%(P=0.044)and 70.3%(P=0.013), respectively, and statistical significant difference was found. The mutation rates of EGFR in the tumors accounted for 68.0% in the female patients(P=0.002)and 69.2% in the non-smoking patients(P=0.000). The pathological subtypes of lung adenocarcinoma in this cohort included: acinar, lepidic, micro-papillary, papillary, solid and infiltrating mucinous subtypes, whose mutation rates of EGFR were 68.5%, 60.9%, 50.0%, 43.8%, 22.2%, and 0.0%, respectively, and statistical significant difference was found(P=0.003). Multivariate logical analysis showed that when all the significant characteristics of EGFR mutations were correlated, the AUC of the ROC curve was 0.718. Conclusion Among the patients with primary lung adenocarcinoma, EGFR mutations tend to occur in women and non-smokers. Mutations of EGFR are mostly in genes 19 and 21, which are prone to occur in the acinar type and lepidic type of lung adenocarcinoma. Mutations of EGFR often occur in the early stage of lung adenocarcinoma. In the terms of MSCT appearance, EGFR mutations more likely occur in the tumors with GGO, spiculation and pleural indentation.

参考文献/References:

1 钱桂生. 肺癌不同病理类型发病率的变化情况及其原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-5.
2 陈艳丽, 王媛媛, 张 勇, 等. 中晚期非小细胞肺癌患者化疗前后T淋巴细胞亚群表达差异分析及临床意义[J/CD]. 中华肺部疾病杂志(电子版), 2020, 13(1): 13-17.
3 李帅帅, 孙 军. 姜黄素对人肝癌细胞BE-7402中环氧合酶-2表达影响的研究[J]. 中国医科大学学报, 2014, 43(3): 222-225.
4 张 英, 李冬梅, 邢 颖. 姜黄素的药理作用与载体研究进展[J]. 中国药房, 2015, 26(13): 1850-1853.
5 Liu S, Wang Z, Xu B, et al. Intermittent hypoxia reduces microglia proliferation and induces DNA damage in vitro[J]. Iran J Basic Med Sci, 2016, 19(5): 497-502.
6 Juergens RA, Brahmer JR. Adjuvant treatment in non-small cell lung cancer: Where are we now?[J]. J Natl Compr Canc Netw, 2006, 4(6): 595-600.
7 李 牧, 王 丽, 刘海莉, 等. 姜黄素通过降低一氧化氮合酶水平抑制宫颈癌HeLa细胞的侵袭和转移[J]. 南方医科大学学报, 2013, 33(12): 1752-1756.
8 Tateishi M, Ishida T, Mitsudomi T, et al. Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung[J]. Cancer Res, 1990, 50(21): 7077-7080.
9 Barker AJ, Gibson KH, Grdundy, et al. Studies leading to the identification of ZD1839?(IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer[J]. Bioorg Med Chem Lett, 2001, 11(14): 1911-1914.
10 朱丛中, 刘 娟, 王新允, 等. 应用组织芯片法检测EGFR、COXZ在肺癌中的表达及生物学意义[J]. 中国肺癌杂志, 2010, 13(2): 107-111.
11 Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis[J]. Cancer Res, 2006, 66(17): 8319-8326.
12 Galera-Ruiz, Rios MJ, Gonzalez-Campora, et al. The cadherin-catenin complex in nasopharyngeal carcinoma[J]. Eur Arch Otorhinolaryngol, 2011, 268(9): 1335-1341.
13 Maseki S, Ijichi K, Tanaka H, et al. Acquisition of EMT phenotype in the gefitinib-resistant cells of a head and neck squamous cell carcinoma cell line through Akt/GSK-3β/snail signalling pathway[J]. Br J Cancer, 2012, 106(6): 1194-1204.
14 Rosano L, Cianfrocca R, Spinella F, et al. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells[J]. Clin Cancer Res, 2011, 17(8): 2350-2360.
15 Foroni C, Broggini M, Generali D, et al. Epithelial-mesenchymal transition and breast cancer: Role, molecular mechanism and clinical impact[J]. Cancer Treat Rev, 2012, 38(6): 689-697.
16 Fu Q, Liu X, Liu Y, et al. MicroRNA-335 and-543 suppress bone metastasis in prostate cancer via targeting endothelial nitric oxide synthase[J]. Int J Mol Med, 2015, 36(5): 1417-1425.
17 Liu S, Wang Z, Xu B, et al. Intermittent hypoxia reduces microglia proliferation and induces DNA damage in vitro[J]. Iran J Basic Med Sci, 2016, 19(5): 497-502.
18 Ranjan AP, Mukerjee A, Gdowski A, et al. Curcumin-ER prolonged subcutaneous delivery for the treatment of non-small cell lung cancer[J]. JBiomed Nanotechnol, 2016, 12(4): 679-688.
19 周晶晶, 郑昱辰, 李明月, 等. 姜黄素的药理作用研究进展[J]. 吉林医药学院学报, 2016, 37(4): 304-307.
20 戴 莉, 杨 炯, 潘雪凯, 等. 姜黄素对肺腺癌 A549 细胞裸 鼠移植瘤的抑制作用及其机制[J]. 中华实验外科杂志, 2016, 33(10): 2358-2361.
21 Chong CR, Jänne PA. The quest to overcome resistance to EGFR-targeted therapies in cancer[J]. Nature Medicine, 2013, 19(11): 1389.
22 李松霖, 谭群友, 王如文, 等. 新型姜黄素纳米粒对 Lewis 肺癌细胞增殖、凋亡的影响[J]. 第三军医大学学报, 2015, 37(2): 141-145.
23 赵 莹, 李英姿. 姜黄素对非小细胞肺癌A459细胞增殖 及CDH13甲基化状态的影响[J]. 山东医药, 2017, 57(6): 9-12.
24 Siddappa G, Kulsum S, Ravindra DR, et al. Curcumin and metformin mediated chemoprevention of oral cancer is associated with inhibition of cancer stem cells[J]. Mol Carcinog, 2017, 56(11): 2446.
25 Li ZC, Zhang LM, Wang HB, et al. Curcumin inhibits lung cancer pro-gression and metastasis through induction of FOXO1[J]. Tumor Biology, 2014, 35(1): 111.
26 Lu Y, Wei C, Xi Z. Curcumin suppresses proliferation and invasion in non-small cell lung cancer by modulation of MTA1-mediated Wnt/β-catenin pathway[J]. In Vitro Cellular & Developmental Biology-Animal, 2014, 50(9): 840.
27 Jin H, Qiao F, Wang Y, et al. Curcumin inhibits cell proliferation and induces apoptosis of human non-small cell lung cancer cells through the upregulation of miR-192-5p and suppression of PI3K/Akt signaling pathway[J]. Oncol Reports, 2015, 34(5): 2782.
28 Wang A, Wang J, Zhang S, et al. Curcumin inhibits the development of non-small cell lung cancer by inhibiting autophagy and apoptosis[J]. Exp Ther Med, 2017, 14(5): 5075.
29 张卫平, 王 珏, 冉 冉. 姜黄素逆转非小细胞肺癌TKI靶向药物耐药机制的研究[J]. 中国现代医生, 2017, 55(25): 37-41.
30 Shishodia S, Chaturvedi MM, Aggarwal BB. Role of Curcumin in Cancer Therapy[J]. Curr Probl Cancer, 2007, 31(4): 243-305.
31 Liu S, Wang Z, Xu B, et al. Intermittent hypoxia reduces microglia proliferation and induces DNA damage in vitro[J]. Iran J Basic Med Sci, 2016, 19(5): 497-502.
32 Rivera M, Ramos Y, Rodríguez-Valentín M, et al. Targeting multiple pro-apoptotic signaling pathways with curcumin in prostate cancer cells[J]. PLoS One, 2017, 12(6): e0179587.

备注/Memo

备注/Memo:
基金项目: 国家自然科学基金资助项目(30972964)
更新日期/Last Update: 2020-06-20